Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.

Gao J, Chang MT, Johnsen HC, Gao SP, Sylvester BE, Sumer SO, Zhang H, Solit DB, Taylor BS, Schultz N, Sander C.

Genome Med. 2017 Jan 23;9(1):4. doi: 10.1186/s13073-016-0393-x.

2.

Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases.

Sylvester BE, Vakiani E.

J Gastrointest Oncol. 2015 Dec;6(6):668-75. doi: 10.3978/j.issn.2078-6891.2015.083. Review.

3.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

4.

The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon.

Grimm WA, Messer JS, Murphy SF, Nero T, Lodolce JP, Weber CR, Logsdon MF, Bartulis S, Sylvester BE, Springer A, Dougherty U, Niewold TB, Kupfer SS, Ellis N, Huo D, Bissonnette M, Boone DL.

Gut. 2016 Mar;65(3):456-64. doi: 10.1136/gutjnl-2014-308735. Epub 2015 Feb 2.

5.

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M.

Clin Cancer Res. 2015 Apr 15;21(8):1935-43. doi: 10.1158/1078-0432.CCR-14-2124. Epub 2014 Oct 28.

6.

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.

Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, Shia J, D'Angelica MI, Weiser MR, Solit DB, Berger MF.

Genome Biol. 2014 Aug 28;15(8):454. doi: 10.1186/s13059-014-0454-7.

7.

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.

Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB.

Cancer. 2014 Aug 1;120(15):2316-24. doi: 10.1002/cncr.28729. Epub 2014 Apr 15.

8.

Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.

Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI.

Clin Cancer Res. 2012 Jan 15;18(2):350-9. doi: 10.1158/1078-0432.CCR-11-1397. Epub 2011 Nov 23.

9.

Race and subset analyses in clinical trials: time to get serious about data integration.

Polite BN, Sylvester BE, Olopade OI.

J Natl Cancer Inst. 2011 Oct 19;103(20):1486-8. doi: 10.1093/jnci/djr382. Epub 2011 Oct 12. No abstract available.

Supplemental Content

Loading ...
Support Center